Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dTzGCfbwoceNncxdCflf

October 8, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • Takeda will boost vaccine business with LigoCyte buyout
    Takeda Pharmaceutical agreed to purchase LigoCyte Pharmaceuticals, which makes vaccines for gastrointestinal and respiratory infections, for $60 million in cash, plus future milestone payments. The acquisition will give Takeda access to LigoCyte's lead candidates, including a norovirus vaccine under Phase I/II development and preclinical-stage vaccines against influenza, rotavirus and respiratory syncytial virus. Genetic Engineering & Biotechnology News (10/5) LinkedInFacebookTwitterEmail this Story
2-Day, $13K Sequencing IDs Genetic Diseases in the NICU
According to the March of Dimes charity, 10-15% of all newborns are admitted to the neonatal intensive care unit (NICU). Many of those babies suffer from genetic disorders. In fact, Stephen Kingsmore told reporters, “the leading cause to admission to the neonatal intensive care unit is an illness that is likely to be genetic.” Find out the details.

  Health Care & Policy 
  • Nobel honors work in cell reprogramming
    The Nobel Prize in physiology or medicine was awarded to John Gurdon of the University of Cambridge and Shinya Yamanaka of the University of Kyoto for the discovery that mature cells can be reprogrammed to become like stem cells. Induced pluripotent stem cells have applications in treatments and pharmaceutical research. Nature/News Blog (10/8), CNN (10/9) LinkedInFacebookTwitterEmail this Story
  • NCBIO president: TPP needs data exclusivity for biologics
    Twelve years of data exclusivity and other intellectual property protections are the keys to the Trans Pacific Partnership's impact on jobs and innovation, North Carolina Biosciences Organization President Sam Taylor writes. "Ensuring that the TPP includes strong protection for intellectual property will help the United States retain its dominance in biopharmaceuticals. It's critical for the administration to push for such protection," Taylor writes. The Herald-Sun (Durham, N.C.) (free registration) (10/6) LinkedInFacebookTwitterEmail this Story
 
  • GSK ends Phase II trial of experimental antibiotic by Anacor
    GlaxoSmithKline and partner Anacor Pharmaceuticals stopped a midstage study of GSK2251052, an antibiotic drug candidate for intra-abdominal and urinary tract infections. Anacor said GSK halted enrollment after finding disease-causing microorganisms that might affect efficacy. Reuters (10/5) LinkedInFacebookTwitterEmail this Story
  • Researchers use ES cells, iPS cells to grow mouse egg cells
    Researchers from Kyoto University's School of Medicine in Japan succeeded in growing mouse egg cells using embryonic stem cells and induced pluripotent stem cells. Tests on female mice showed the cells allowed the animals to bear normal and fertile offspring, according to the study published in Science. "Our system serves as a robust foundation to investigate and further reconstitute female germline development in vitro," the researchers said. ScientificAmerican.com/Observations blog (10/4) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  • French biotech corn study is scientifically unsound, EFSA says
    A French study connecting Monsanto's biotech corn to risks of cancer and early death is "of insufficient scientific quality to be considered as valid for risk assessment," according to the European Food Safety Authority. In its first analysis of the research, EFSA found inadequacies in the study's design, reporting and analysis. The flaws make the study's conclusions scientifically unsound, the agency said. FoodNavigator (10/4), Fox Business/Dow Jones Newswires (10/4) LinkedInFacebookTwitterEmail this Story
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • Cellulosic ethanol plants are being commissioned and built
    Though cellulosic ethanol plant construction schedules can be uncertain and fluid, a series of forward steps to be in the works in the U.S. and Canada by 2014, according to data compiled by Ethanol Producer Magazine. Ineos Bio and Chemtex International are commissioning advanced-biofuel plants, while BlueFire Renewables and Abengoa BioEnergy are among the companies that are building or planning to build plants. EthanolProducer.com (10/5), EthanolProducer.com (10/5) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
The ability to deal with people is as purchasable a commodity as sugar or coffee and I will pay more for that ability than for any other under the sun."
--John D. Rockefeller,
American industrialist and philanthropist


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information